Business Of Biotech
Biotech Is Back with Allan Shaw
Jan 29, 2024
Renowned biotech CFO, Allan Shaw, shares the reasons behind cautious optimism for biotech's return, including December's M&A activity, interest rate reductions, and easing inflation. They also discuss the election year wildcard and the potential benefits of a metered biotech comeback. The podcast explores topics such as the impact of AI and ML in biotech, the evolution and significance of the JP Morgan conference, and the current state of the industry and innovations.
51:02
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Biotech is experiencing a comeback, driven by positive market sentiments and increased M&A activity to solve pipeline issues.
- The JP Morgan conference remains significant as a platform for reconnecting with industry professionals, exploring business opportunities, and networking.
Deep dives
Biotech Making a Comeback
Biotech is experiencing a comeback, as indicated by positive market sentiments and evidence such as a rally at the end of the year and increased buy-side engagement. The recent surge in M&A activity suggests that Big Pharma is looking to solve pipeline issues. Although there is cautious optimism, the sentiment remains that the industry is not fully out of the woods yet. The impact of the upcoming election and ongoing concerns about drug pricing also contribute to the uncertain environment. However, there is excitement about scientific and technical advances, including the use of AI and machine learning in biotech. Despite challenges, there is a focus on fundamentals, execution, and finding innovative solutions to chronic diseases.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
